An identical proportion of patients in both treatment groups were alive at 12 months in the CheckMate 143 trial Overall survival (OS) was not different in patients with recurrent glioblastoma who received single-agent immune...
Read More
Few prospective studies on outcomes in CSCC have been performed, and outcomes for patients treated...
Read More
THURSDAY, May 21, 2020 (HealthDay News) — Clinically important increases in melanoma risk in...
Read More WEDNESDAY, May 20, 2020 (HealthDay News) — Prostate cancer incidence rates decreased from...
Read More WEDNESDAY, May 20, 2020 (HealthDay News) — Childhood body mass index (BMI) is positively...
Read MoreThree days packed with presentations The American Society of Clinical Oncology is the leading oncology research meeting worldwide, but just like other medical conferences, ASCO 2020 was forced to make many changes to deliver on...
Read MoreNew option for BRCA-mutation associated mCRPC PARP (poly ADP ribose polymerase) inhibitors, which are well-recognized for efficacy in treating breast and ovarian cancers, are now demonstrating efficacy in prostate cancer —...
Read More
Research has shown that obesity accelerates the development of certain cancers, including cancers...
Read MoreNew drug ups progression-free survival but comes with long list of side effects WASHINGTON — The FDA approved ripretinib (Qinlock) tablets, the first drug indicated as a fourth-line treatment for patients with advanced...
Read More